Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Investments in PP&E?

  Amgen Inc ( AMGN ) |
1989 - 2021 (33 years)

Investments in PP&E is 
-$959.3M (1Y +19.9% )

AMGN Stock Price & Investments in PP&E

Investments in PP&E for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Investments in PP&E

chevron_right 2021 -$173.0M +4.3x
( +5.2% / year avg)
chevron_left 1989 -$32.9M
vertical_align_top Peak -$32.9M +0.98x
vertical_align_bottom Bottom -$1.5B
arrow_drop_up # Up Years 18 18 of 33
years up.
arrow_drop_down # Down Years 15
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1989 , or +263x faster than it's investments in pp&e over the same period.
  • If AMGN grows it's stock at the same rate as it's investments in pp&e (+5.2%/year) , it's stock price will grow +166% and hit $409.65 over the next 10 years.
  • AMGN's stock price has gone up 13 of the 18 years (+72%) it's investments in pp&e were also up.
  • AMGN Historical Investments in PP&E Table

    Year Investments in PP&E YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 -173,000,000.0 -81.3% $246.75 0.0%
    4/1/2020 -923,000,000.0 40.9% $246.75 7.3%
    4/1/2019 -655,000,000.0 -1.7% $229.96 16.1%
    4/1/2018 -666,000,000.0 -20.4% $198.0 22.0%
    4/1/2017 -837,000,000.0 16.9% $162.25 25.3%
    4/1/2016 -716,000,000.0 -8.4% $129.45 -8.2%
    4/1/2015 -782,000,000.0 -9.7% $141.03 -0.6%
    4/1/2014 -866,000,000.0 25.1% $141.87 47.7%
    4/1/2013 -692,000,000.0 -2.9% $96.04 30.8%
    4/1/2012 -713,000,000.0 35.8% $73.4 56.3%
    4/1/2011 -525,000,000.0 -3.1% $46.96 11.0%
    4/1/2010 -542,000,000.0 -3.9% $42.29 -6.5%
    4/1/2009 -564,000,000.0 -22.5% $45.23 1.5%
    4/1/2008 -728,000,000.0 -48.6% $44.58 0.5%
    4/1/2007 -1,417,000,000.0 28.9% $44.34 -22.2%
    4/1/2006 -1,099,000,000.0 22.4% $57.02 -12.2%
    4/1/2005 -898,000,000.0 -38.7% $64.96 34.8%
    4/1/2004 -1,465,300,000.0 23.3% $48.19 4.2%
    4/1/2003 -1,188,100,000.0 122.8% $46.25 22.1%
    4/1/2002 -533,200,000.0 23.9% $37.88 -28.9%
    4/1/2001 -430,200,000.0 35.3% $53.32 4.4%
    4/1/2000 -318,000,000.0 -18.9% $51.07 39.6%
    4/1/1999 -392,000,000.0 -5.7% $36.57 142.2%
    4/1/1998 -415,800,000.0 6.3% $15.1 47.2%
    4/1/1997 -391,300,000.0 75.1% $10.26 -16.0%
    4/1/1996 -223,500,000.0 55.3% $12.21 22.7%
    4/1/1995 -143,900,000.0 53.6% $9.96 70.0%
    4/1/1994 -93,700,000.0 -55.4% $5.86 27.9%
    4/1/1993 -209,900,000.0 -4.5% $4.58 -31.6%
    4/1/1992 -219,800,000.0 147.5% $6.7 11.3%
    4/1/1991 -88,800,000.0 61.2% $6.02 317.4%
    4/1/1990 -55,100,000.0 67.5% $1.44 98.3%
    4/1/1989 -32,900,000.0 - $0.73 -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

  • Investments made to PP&E.

    Property, plant, and equipment (PP&E) are long-term assets vital to business operations and not easily converted into cash. Property, plant, and equipment are tangible assets, meaning they are physical in nature or can be touched. The total value of PP&E can range from very low to extremely high compared to total assets.

    For more detailed definitions, please see Investopedia.